Dr Patrick Treacy attends European Special Convention on Lipodissolve Injections in Dortmund, GERMANY

A number of well known medical specialists – ranging from cosmetic doctors, dermatologists and plastic surgeons from differing European countries recently came together to hold the fourth European Special Convention on “Lipodissolve Injections”. Several specialized lectures were held on NETWORK-Lipolysis, and covered the legal aspects of the therapy as well as information about the lipodissolve therapy itself. Dr. Treacy is a member of NETWORK-Lipolysis, a global association of physicians who have been certified in the use of lipodissolve injections by European expert, Dr Franz Hasenschwandtner.

From left to right: Dr. med. Spyridon Joannides Greece Plastic Surgery, Dr. Franz Hasengschwandtner Austria, Dr Patrick Treacy Ireland

Dr Hasenschwandtner is the leading research director in Europe in Lipodissolve procedures with over 2,000 clinical procedures to date. He is the President of the German association for adiposis research and has over 15 years experience with intravenous Phosphatidyl Choline and other substances used in Lipodissolve. He also trains all the members of our NETWORK both in theory and practice and this supports the provision of consistent treatment of a high standard by all NETWORK members. In addition the members, ranging from general practitioners to specialists in plastic surgery, all contribute to lipodissolve research by exchanging their specific knowledge and experience.

When you undergo a treatment with a physician certified by our NETWORK clinical details and treatment efficacy will be reported, strictly anonymously to the NETWORK-Lipolysis data bank. This enables all physicians of the NETWORK to take part in a frontier-crossing follow-up study about individual responses and tolerances. Several detailed studies about lipodissolve injections are in preparation by physicians of the NETWORK. The convention reported a non-responder rate of about 5%, (i.e. the therapy does not show any effect in about one in twenty patients). The reasons for this are unknown.